Background: Angiogenesis plays an important role in the occurrence, development, invasion and metastasis of tumors. Bevacizumab is a monoclonal antibody targeting VEGF-A and the first approved anti-angiogenic drug, which was approved in July 2015 for the first-line treatment of advanced non-squamous NSCLC in China. However, for the treatment of recurrent NSCLC, the clinical application value of bevacizumab needs further verification and analysis. Method: The data of 43 patients with advanced non-squamous NSCLC in the Tumor Hospital of Jilin province from April 2013 to April 2017 were retrospectively analyzed. All the patients were diagnosed by pathology or cytology and were clinically attribute to stage IV, and were treated with the combination of pemetrexed or gemcitabine or docetaxel or vincristine combined with bevacizumab (carboplatin or cisplatin) regimen. The dosage of bevacizumab was 7.5mg/kg, every 3 weeks. 20 patients were treated with second-line treatment and 23 were treated with second -and third-line treatment. There were 17 cases with positive mutation of epidermal growth factor receptor (EGFR) and 26 cases with negative mutation. The efficacy and safety of bevacizumab combined with chemotherapy were evaluated in 17 cases of brain metastases, including 8 cases with related symptoms. Univariate and multivariate analyses were performed on the factors that may affect the prognosis. Results: A total of 43 patients were included with an objective remission rate of 18.6% and a disease control rate of 74.4%. Median progression-free survival was 5.4 months and median overall survival was 11.7 months. In the subgroup analysis, there was no statistically significant difference in median PFS between patients with positive and negative epidermal growth factor receptor (EGFR) mutation and those with negative mutation. The difference in median PFS between patients with brain metastasis and those without brain metastasis was no statistically significant (5.2 months vs. 5.4 months, P¼0.052). In the group of patients who use bevacizumab more than 3 cycles, the median progression-free survival was 9.1 months, the median progression-free survival was 14.2 months; but in those who use less, the median progression-free survival was 4.3 months, and the median progression-free survival was 10.2 months. The application period of bevacizumab (more than 4 cycles or not) is an independent factor influencing PFS (P¼0.004). The common adverse events during the treatment with bevacizumab include hypertension, proteinuria and hemorrhage, most of which are grade 1-2. Conclusion: Bevacizumab combined with chemotherapy can improve the survival and safety of patients with second-line and above advanced non-squamous NSCLC. Background: Previous studies have demonstrated that circulating tumor cell (CTC) might work as an alternative to biopsy tissues in the diagnoses of small cell lung cancer (SCLC). Programmed death ligand 1 (PD-L1) is one of the most commonly used biomarkers in immune targeted therapies. However, the expression of PD-L1 in CTC is still unknown. This study aimed to establish an approach to measure PD-L1 in peripheral CTCs from SCLC patients. Method: Control cells were screened by monoclonal culture and confirmed by immunohistochemistry (IHC) staining and flow cytometry. PD-L1 expression in CTCs and tumor tissue samples from SCLC patients was measured by CellSearch system while the usage of PD-L1 antibody was optimized. Results: The purity of PD-L1 positive H446 cells had been improved from 70% to 95% by clonal selection, and PD-L1 negative PC3 cells showed lower than 5% purity. In CellSearch system, positive control cells had 98% PD-L1 expression while negative control had less than 3% expression. In two SCLC patients with CTC positive expression, PD-L1 expression was found with 100% (1/1) and 40% (2/5) positive rate. Conclusion: CellSearch system was used to establish a novel approach for measuring surface PD-L1 expression on CTC, and showed supporting evidences in SCLC patients, thus providing novel insights for automatic assay of PD-L1 in peripheral samples. 
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-MDSCs level was elevated in peripheral blood of SCLC patients and has a prognostic value for SCLC patients. In this study we further explored the mechanisms of SCLCderived MDSCs involved in angiogenesis. Method: Peripheral blood specimens from SCLC patients and healthy volunteer were collected and CD11b + /CD33 + cells were separated using magnetic bead. Giemsa stain was used in morphological identification of the cells. CD11b Abstracts S1061
